What are postbiotics, and do they actually work?

In 2021, the International Scientific Association for Probiotics and Prebiotics (ISAPP) published a formal consensus definition: a postbiotic is "a preparation of inanimate microorganisms and/or their components that confers a health benefit on the host"¹. This established a clear scientific boundary between postbiotics and the broader category of fermentation byproducts.

Postbiotics include several distinct classes of compounds:

• Short-chain fatty acids (SCFAs): Butyrate, propionate, and acetate are the primary SCFAs produced when gut bacteria ferment dietary fiber. SCFAs can enhance the production of mucins, antimicrobial proteins, and cytokines such as interleukin 10 and 18, helping to maintain the gut barrier and immune function⁵.
• Heat-killed bacteria: Whole bacterial cells that have been inactivated by heat or UV light. Even without being alive, these cells can interact with Toll-like receptors on immune cells, triggering beneficial immune responses³.
• Cell wall components: Peptidoglycan fragments, lipoteichoic acids, and teichoic acids from bacterial cell walls can modulate innate immune signaling.
• Exopolysaccharides: Long-chain sugars secreted by bacteria that interact with gut mucosa and immune tissue.
• Bacteriocins and bioactive peptides: Natural antimicrobial compounds produced by beneficial bacteria that help suppress pathogens.

How Postbiotics Support Gut Health

The gut lining is only one cell thick, and keeping it intact is essential — a compromised barrier is associated with conditions ranging from IBS to autoimmunity. Postbiotics contribute to barrier integrity through several mechanisms^2,4.

Short-chain fatty acids could enhance the production of mucins in the intestine, which helps maintain the intestinal barrier⁵.

Heat-killed bacteria cells signal through pattern recognition receptors on dendritic cells and macrophages in the gut wall. This priming effect helps the immune system maintain appropriate tolerance to beneficial bacteria while staying alert to genuine pathogens — essentially calibrating the gut immune response without the unpredictability of live organisms³.

The Advantage Over Live Probiotics

Live probiotics have one significant limitation: they must survive transit through the stomach's acid and bile salts to reach the colon. Many clinical trials with probiotics suffer from inconsistency because different strains survive at different rates, and manufacturing quality varies widely.

Postbiotics sidestep this entirely. Heat-killed cells and purified metabolites are already in their active form — they don't need to survive, colonize, or replicate to work^1,2. This makes postbiotics particularly relevant for:

• People with immune compromise who should not take live bacterial preparations
• Infants, where postbiotic-enriched formulas have been used in clinical settings
• Anyone who needs a standardized, consistent dose without variability from viability

Where Postbiotics Come From — Food and Supplements

You encounter postbiotics every time you eat fermented foods, even if the live cultures don't survive storage or digestion. The metabolic byproducts remain in the food — the organic acids in yogurt, the bacteriocins in aged cheese, the SCFAs in kefir, sauerkraut, and miso all count as postbiotics².

As supplements, postbiotics typically take the form of:

• Standardized SCFA formulations (butyrate capsules, often as sodium or calcium butyrate, or the more bioavailable tributyrin form)
• Heat-killed Lactobacillus or Bifidobacterium preparations standardized for cell count
• Fermented extracts concentrated for specific bioactive fractions

See the Fermented Foods section and Butyrate page for complementary approaches to supporting your gut microbiome.

ISAPP Consensus Definition (Salminen et al., 2021)

The formal scientific definition of postbiotics emerged from an expert panel convened by the International Scientific Association for Probiotics and Prebiotics, published in Nature Reviews Gastroenterology & Hepatology¹. The panel of 11 scientists reviewed the existing literature across thousands of studies and concluded that the term "postbiotic" had been used inconsistently — sometimes to mean only metabolic byproducts, sometimes to include whole inactivated cells. The consensus definition they settled on — "a preparation of inanimate microorganisms and/or their components that confers a health benefit on the host" — requires both inactivation and demonstrated health benefit, distinguishing postbiotics from mere fermentation byproducts. Critically, purified metabolites like free butyrate do not qualify as postbiotics under this definition, since the source microorganism must be present in some form. This definitional clarity has been foundational for subsequent clinical research, allowing trials to be more precisely designed and compared.

Mechanisms and Clinical Characteristics (Żółkiewicz et al., 2020)

This comprehensive review in Nutrients examined the accumulated clinical and mechanistic evidence for postbiotics at the time of publication, covering studies from 2010 through 2019². The authors identified several well-characterized mechanisms through which postbiotics exert health effects: modulation of gut microbiota composition, enhancement of epithelial barrier function (via tight junction protein upregulation), suppression of pro-inflammatory cytokines (particularly IL-6, TNF-α, and IL-12), and direct antimicrobial activity through bacteriocins. The review noted that heat-killed Lactobacillus acidophilus and Bifidobacterium species had the most robust human evidence at the time, particularly for pediatric diarrhea, IBS symptom reduction, and atopic dermatitis. The authors highlighted a key advantage of postbiotics over live probiotics: because postbiotics are not affected by antibiotic co-administration, they may be used alongside antibiotic therapy where live probiotics might be killed before reaching the colon.

Immune Modulation Review (Mehta et al., 2023)

This 2023 review in Microbiology Research focused specifically on the immunological dimension of postbiotic activity³. The authors reviewed evidence from both in vitro and human trials covering heat-killed bacteria, exopolysaccharides, bacteriocins, and SCFA preparations. Key findings included: postbiotic components promote differentiation of regulatory T cells (Tregs), which dampen excessive immune activation; they modulate macrophage polarization toward the anti-inflammatory M2 phenotype; and they interact with plasmacytoid dendritic cells to upregulate interferon production, which has implications for antiviral defense. The review noted that lipoteichoic acids from gram-positive bacteria are among the most potent immunomodulatory postbiotic components, capable of activating NF-κB and mitogen-activated protein kinase pathways. The authors emphasized that the dose-response relationship for postbiotics is not linear — immunostimulatory effects depend on the specific structural features of the bacterial cell wall, not just quantity, which has important implications for product standardization.

Clinical Evidence Review (Mosca et al., 2022)

This review in Gut Microbes examined the clinical evidence for postbiotics in highly prevalent conditions and considered future areas of benefit⁴. The authors noted that probiotic use in vulnerable people is linked to possible safety concerns and that maintaining probiotic viability is difficult, which is why interest in postbiotics is increasing; postbiotics contain inactivated microbial cells or cell components, so they are more stable and exert similar health benefits to probiotics. They concluded that there is growing evidence of diverse clinical benefits of postbiotics in many prevalent conditions, that postbiotics could offer a novel therapeutic approach and may be a safer alternative to probiotics, and that establishing how postbiotics interact with commensal microorganisms will improve understanding of their potential clinical benefits and may lead to targeted postbiotic therapy.

Short-Chain Fatty Acids as Gut Mediators (Ragavan and Hemalatha, 2024)

This review discussed the functional roles of short-chain fatty acids (SCFAs) as postbiotics in the human gut, along with future perspectives⁵. The authors describe the gut microbiome and its metabolites (postbiotics) as a potentially promising approach to treating diseases that include inflammatory bowel diseases, colon cancer, and many neurological disorders. They note that probiotic bacteria such as Lactobacillus and Bifidobacterium have been demonstrated to produce SCFAs, and that these acids could enhance the production of mucins, antimicrobial proteins (bacteriocins and peptides), cytokines (interleukin 10 and 18), and neurotransmitters (serotonin) in the intestine, helping to maintain the gut microbiota, the intestinal barrier, and other immune functions. The review discusses two mechanisms as routes to therapeutic options for treating or preventing various diseases: SCFA-mediated support of the intestinal barrier, and SCFA-mediated effects on the gut–brain axis.